Skip to main content
. 2011 Apr 12;117(23):6267–6276. doi: 10.1182/blood-2010-12-324004

Figure 4.

Figure 4

Expression of the new markers before, during and at the end of remission induction therapy. Symbols indicate mean fluorescence intensity (MFI) of each marker as measured on ALL cells at diagnosis and on residual leukemic lymphoblasts detected on days 19 and 42 of remission induction therapy. At all time points, all markers were expressed at levels that exceeded those measured in normal CD19+CD10+ cells.

HHS Vulnerability Disclosure